Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nektar Therapeutics reports strong Q1 results and advances pipeline

Nektar Therapeutics demonstrated solid financial performance in Q1 2024, with a positive revenue outlook for the full year.
The company's pipeline strength lies in REZPEG's promising results, NKTR-255's progress, and the advancement of NKTR-0165.
Challenges include patient selection complexities and timing uncertainties, while opportunities exist in therapeutic optimization and pipeline expansion.
Overall, Nektar remains focused on advancing its immunology programs and leveraging its financial stability for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

I-Mab

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHERSBURG, MD , April 28, 2022 /PRNewswire/ --I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced today the appointments of Mr.

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

Bristol-Myers

Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.  Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his.

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.

Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure

Shares of Nektar Therapeutics NKTR, +3.51% were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. As of Dec. 31, the company employed 740 workers.

Nektar to reduce workforce by 70%

Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT) SAN FRANCISCO , April 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company's future, including its NKTR-358, NKTR-255 and several core research programs. In connection with this new strategic plan, Nektar also announced a cost restructuring plan aimed at ensuring Nektar has significant capital to fund key programs through value-enhancing data and other milestones without a need to raise incremental capital for at least 3 years.

Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook

SAN FRANCISCO , April 23, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor activities of different CAR-T therapies in a variety of cancer preclinical models. Presentations include an oral presentation by Wen Luo, Ph.D.

Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

SAN FRANCISCO , April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan

The company is throwing in the towel on its lead pipeline program.

Why Nektar Therapeutics Stock Is Crashing Today

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.

Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures

Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's BMY, -1.20% Opdivo. The combination was being tested in several types of cancer, including renal cell carcinoma and urothelial carcinoma.

Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo

Nektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb's Opdivo.

Nektar Therapeutics Stock Tanks Nearly 40%

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.  The decision follows the results from pre-planned analyses of two late-.

Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program

Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market trading.

Nektar stops clinical trials for key cancer drug, shares tumble

PRINCETON, N.J. and SAN FRANCISCO , April 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb  (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Why Is Nektar (NKTR) Down 47.6% Since Last Earnings Report?

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure

Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?

Why is Nektar Therapeutics (NKTR) Stock Down Today?

A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

Why Nektar Therapeutics Stock Is Imploding Today

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma.

Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit

Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY), did not meet its primary endpoint. Following a review of the study for efficacy and safety by an.

Why Nektar Therapeutics Shares Are Falling Today

Cancer drug bempeg was an important one for biotech Nektar and its partner Bristol Myers Squibb.

Nektar Shares Halve on Cancer Trial Failure

SAN FRANCISCO, March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma.

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

Shares of Nektar Therapeutics Inc. NKTR, -2.74% tumbled 44.7% in premarket trading on Monday after the company said a combination of its experimental therapy bempegaldesleuk in combination with Bristol Myers Squibb Co.'s BMY, +0.66% Opdivo failed as a treatment for melanoma. The companies had tested the combination against Opdivo in a Phase 3 clinical trial as a first-line treatment for patients with previously untreated unresectable or metastatic melanoma.

Nektar's stock falls 44% after experimental therapy fails to work in melanoma patients

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

News for Nektar Therapeutics Stock (NKTR)